Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMC5RKY)

Drug Name
Concatameric CTLA4Ig Drug Info
Synonyms Concatameric CTLA4Ig (Immunoadhesin); Concatameric CD152Ig (Immunoadhesin), Medexgen; Concatameric CTLA4Ig (Immunoadhesin), Medexgen
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
TTD Drug ID
DMC5RKY

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Cytotoxic T-lymphocyte protein 4 (CTLA-4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ipilimumab DMJTIYK Melanoma 2C30 Approved [2]
Tremelimumab DMOQ9H1 Hepatocellular carcinoma 2C12.02 Approved [1]
KN046 DMSDBPG Non-small-cell lung cancer 2C25.Y Phase 3 [3]
AK04 DMU7K86 Actinic keratosis EK90.0 Phase 3 [4]
AK104 DMXJ8Z4 Cervical cancer 2C77.0 Phase 2 [5]
Lorigerlimab DM2E8Z5 Prostate cancer 2C82.0 Phase 2 [6]
Vudalimab DMSEEI0 Prostate cancer 2C82.0 Phase 2 [7]
AGEN1884 DMAP5B4 Cervical cancer 2C77.0 Phase 1/2 [8]
BMS-986288 DMM10J4 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [9]
MK-1308 DM25QKC Solid tumour/cancer 2A00-2F9Z Phase 1/2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cytotoxic T-lymphocyte protein 4 (CTLA-4) TTI2S1D CTLA4_HUMAN Modulator [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743).
2 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
3 Clinical pipeline report, company report or official report of Alphamab Oncology.
4 A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study). Lung Cancer. 2023 Oct;184:107355.
5 Clinical pipeline report, company report or official report of Akeso Biopharma.
6 Clinical pipeline report, company report or official report of MacroGenics
7 Clinical pipeline report, company report or official report of Xencor
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Clinical pipeline report, company report or official report of CytomX Therapeutics.
10 Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021 Mar;32(3):395-403.